Genferon light vaginal/rectal suppositories 250t IU No. 10
Genferon light vaginal/rectal suppositories 250t IU No. 10
Genferon Light Buy Genferon Light in pharmacies
DOSAGE FORMS suppositories for vaginal or rectal administration 250000IU+5mg
MANUFACTURERS Biocad CJSC (Russia)
GROUP Antiviral - interferons
COMPOSITION Interferon alpha-2b, taurine.
INTERNATIONAL NON-PROPENTED NAME Interferon alpha-2b+Taurine
PHARMACOLOGICAL ACTION Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of β-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
INDICATIONS FOR USE For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.
CONTRAINDICATIONS Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of using the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.
SIDE EFFECTS Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur with the use of all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.
INTERACTION The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect
METHOD OF APPLICATION AND DOSAGE The drug can be used both vaginally and rectally. The method of administration, dosage and course duration depend on age, the specific clinical situation and are determined by the attending physician.
OVERDOSE In case of accidental simultaneous administration of more suppositories than prescribed by the doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
SPECIAL INSTRUCTIONS The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
STORAGE CONDITIONS Store at a temperature of 2 to 8 degrees. C. Keep out of the reach of children.
Genferon Light nasal drops 10000IU/ml+0.8 mg/ml fl.10ml
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Compound
Bottle 10 mlInterferon alpha-2b 10000 IU, taurine 0.8 mg.
pharmachologic effect
The drug Genferon Light, nasal drops, has antiviral, immunomodulatory, anti-inflammatory, antiproliferative, antibacterial effects, has local regenerating, membrane-stabilizing and antioxidant properties. Interferon alpha blocks the proliferation of viruses at the stage of synthesis of specific proteins and prevents infection of uninfected cells of the nasal mucosa, which is the site of pathogen invasion and the primary focus of inflammation during respiratory infections. The immunomodulatory effect is manifested by an increase in cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against foreign agents. This is achieved through the activation of CD8+ T-killers, NK cells (natural killer cells), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the main histocompatibility complex type 1, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced by the iodine influence of interferon. Taurine, which is part of the drug, normalizes metabolic processes in tissues, promotes regeneration and faster restoration of the nasal mucosa, damaged by the pathological process.
Indications for use
Treatment of influenza and other acute respiratory viral infections in children aged 29 days to 14 years.
Mode of application
At the first signs of the disease, Genferon Light is instilled into the nose for 5 days. Children from 29 days to 11 months 29 days - 1 drop in each nasal passage 5 times a day (single dose 1,000 IU, daily dose 5,000 IU). Children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2,000 IU. daily dose 6,000-8,000 IU). Children from 3 to 14 years old - 2 drops in each nasal passage 4- 5 times a day (single dose 2,000 IU, daily dose - 8,000-10,000 IU).
Interaction
The simultaneous use of intranasal vasoconstrictor drugs is not recommended, as this causes additional dryness of the nasal mucosa.
Side effect
Local allergic reactions (burning sensation, itching) are possible. These phenomena are reversible and disappear on their own within 72 hours after stopping the use of the drug. Continuation of treatment is possible only after consultation with a doctor.
Contraindications
- hypersensitivity to interferon alfa-2b or other components of the drug; - newborns from 0 to 28 days (due to the lack of clinical data).
Overdose
Cases of overdose of the drug Genferon Light have not been registered to date.
special instructions
After instillation, it is recommended to massage the wings of the nose with your fingers for several minutes to evenly distribute the drug in the nasal cavity. Effect on the ability to drive vehicles and operate machinery. The effect of the drug Genferon Light on the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machine equipment, etc.) have not been studied.
Dispensing conditions in pharmacies
On prescription
Genferon supp 1000000 IU cor x10
Trade name: Genferon International name: (not specified) ( (not specified))
Release forms: suppositories 250000, 500000, 1000000 IU (contour cell packaging)
Ingredients: human recombinant interferon alpha-2 250/500/1000 thousand IU, benzocaine 55 mg, taurine 10 mg
Pharmacological group: immunomodulatory agent
Pharmacological group according to ATK: L03AB (Interferons)
Pharmacological action: antioxidant, immunostimulating, membrane stabilizing, antiviral, anti-inflammatory, antimicrobial, immunomodulating,
Description: Suppositories from white to white with a yellowish tint, cylindrical in shape with a pointed end.
Indications: As part of complex therapy for infectious and inflammatory diseases of the urogenital tract: genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, recurrent vaginal candidiasis, gardnerellosis, trichomoniasis, human papillomavirus infections, bacterial vaginosis, cervical erosion, cervicitis, vulvovaginitis, bartholinitis, adnexitis, prostatitis , urethritis, balanitis, balanoposthitis.
Dosage regimen: 1. Infectious and inflammatory diseases of the urogenital tract in women. 1 suppository (250,000 IU or 500,000 IU depending on the severity of the disease) vaginally 2 times a day every day for 10 days. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months. 2. Infectious and inflammatory diseases in men. Rectally, 1 suppository (500,000 IU or 1,000,000 IU depending on the severity of the disease) 2 times a day for 10 days.
Contraindications: Individual intolerance to interferon and other substances included in the drug.
Side effects: Allergic reactions, namely skin rashes and itching. These phenomena are reversible and disappear 72 hours after stopping administration or reducing the dose. Phenomena that occur with the use of all types of interferon alpha-2 may also be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia, but they are more common when administering a dose of more than 10 million IU daily.
Pharmacodynamics: a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects. Interferon alpha-2 has antiviral, antimicrobial and immunomodulatory effects. Under the influence of interferon alpha-2, the activity of natural killer cells, T-helper cells, phagocytes, as well as the intensity of differentiation of B-lymphocytes in the body increases. Activation of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of primary pathological foci and ensures restoration of the production of secretory immunoglobulin A. Interferon alpha-2 also directly inhibits the replication and transcription of viruses and chlamydia. Taurine, which is part of the drug, has regenerating, reparative, membrane- and hepatoprotective, antioxidant, and anti-inflammatory properties. Anestezin is a local anesthetic. Reduces the permeability of the cell membrane to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers.
Pharmacokinetics: When administered vaginally or rectally, interferon alfa-2 is absorbed through the mucous membrane, enters the surrounding tissues, and enters the lymphatic system, providing a systemic effect. Also, due to partial fixation on the cells of the mucous membrane, it has a local effect. A decrease in the level of serum interferon 12 hours after administration of GENFERON® necessitates its repeated administration.
Interaction: GENFERON® is most effective in combination with medications (including antibiotics and other antimicrobial drugs) used to treat urogenital diseases. It is recommended to simultaneously use vitamins E and C, which enhance the effect of interferon. Non-narcotic analgesics and anticholinesterase drugs enhance the effect of anesthesin. Anestezin reduces the antibacterial activity of sulfonamides.
Storage conditions: At a temperature of 2-8 °C
Shelf life: 1 year
Dispensed from pharmacies: By prescription.
Drug registration number: P No. 001812/01
Date of registration (re-registration) of the drug: 09/01/2004
